TY - JOUR
T1 - Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma
AU - Kim, Dong W.
AU - Chung, Kwangzoo
AU - Chung, Weon K.
AU - Bae, Sun H.
AU - Shin, Dong O.
AU - Hong, Seongeon
AU - Park, Sung H.
AU - Park, Sung Yong
AU - Hong, Chae Seon
AU - Lim, Young K.
AU - Shin, Dongho
AU - Lee, Se B.
AU - Lee, Hyun ho
AU - Sung, Jiwon
AU - Yoon, Myonggeun
N1 - Funding Information:
This work was supported by the General Researcher Program (NRF-2012R1A1A2003174); the Nuclear Safety Research Program (Grant No. 1305033) through the Korea Radiation Safety Foundation (KORSAFe) and the Nuclear Safety and Security Commission (NSSC); the Radiation Safety Program (2011–31115); and Radiation Technology Development Program (2013M2A2A4027117), Republic of Korea.
PY - 2014/5/8
Y1 - 2014/5/8
N2 - Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.
AB - Purpose: To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).Methods: Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.Results: The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 104 person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.Conclusions: We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.
KW - EAR
KW - ERR
KW - HCC
KW - IMRT
KW - LAR
KW - OED
KW - Radiophotoluminescence
KW - Tomotherapy
KW - VMAT
UR - http://www.scopus.com/inward/record.url?scp=84901246509&partnerID=8YFLogxK
U2 - 10.1186/1748-717X-9-109
DO - 10.1186/1748-717X-9-109
M3 - Article
C2 - 24886163
AN - SCOPUS:84901246509
SN - 1748-717X
VL - 9
JO - Radiation Oncology
JF - Radiation Oncology
IS - 1
M1 - 109
ER -
